Blockade of Tumor-Expressed PD-1 promotes lung cancer growth

ABSTRACT Anti-PD-1 immunotherapy is the standard of care for treating many patients with non-small cell lung cancer (NSCLC), yet mechanisms of treatment failure are emerging. We present a case of NSCLC, who rapidly progressed during a trial (NCT02318771) combining palliative radiotherapy and pembrolizumab. Planned tumor biopsy demonstrated PD-1 expression by NSCLC cells. We validated this observation by detecting PD-1 transcript in lung cancer cells and by co-localizing PD-1 and lung cancer-specific markers in resected lung cancer tissues. We further investigated the biological role of cancer-intrinsic PD-1 in a mouse lung cancer cell line, M109. Knockout or antibody blockade of PD-1 enhanced M109 viability in-vitro, while PD-1 overexpression and exposure to recombinant PD-L1 diminished viability. PD-1 blockade accelerated growth of M109-xenograft tumors with increased proliferation and decreased apoptosis in immune-deficient mice. This represents a first-time report of NSCLC-intrinsic PD-1 expression and a potential mechanism by which PD-1 blockade may promote cancer growth.

• Publication year

  2017

• Venue

  Oncoimmunology

• Publication date

  2017-11-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/2162402X.2017.1408747PMID 29632720PMCID 5889288
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Shp2 Inhibits Proliferation of Esophageal Squamous Cell Cancer via Dephosphorylation of Stat3

  2017cited by this paper
• PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1

  2017cited by this paper
• Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy

  2017cited by this paper
• Can an Immune Checkpoint Inhibitor (Sometimes) Make Things Worse?

  2017cited by this paper
• Leading Edge Review Primary , Adaptive , and Acquired Resistance to Cancer Immunotherapy

  2017cited by this paper
• Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells

  2017cited by this paper
• Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.

  2017cited by this paper
• Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate

  2017cited by this paper
• Tumor Cell–Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy

  2017cited by this paper
• Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.

  2017cited by this paper
• Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

  2017cited by this paper
• Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

  2017cited by this paper
• Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

  2017cited by this paper
• PD-L1 is a diverse molecule regulating both tumor-intrinsic signaling and adaptive immunosuppression.

  2016cited by this paper
• Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non–Small Cell Lung Cancers In Vitro and In Vivo

  2016cited by this paper
• Stereotactic Body Radiation Therapy Delivery in a Genetically Engineered Mouse Model of Lung Cancer.

  2016cited by this paper
• Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy

  2016cited by this paper
• Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

  2016cited by this paper
• Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

  2016cited by this paper
• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

  2016cited by this paper
• Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Expression Atlas update—an integrated database of gene and protein expression in humans, animals and plants

  2015influential reference
• Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer

  2015influential reference
• Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.

  2015cited by this paper
• Biochemical Signaling of PD-1 on T Cells and Its Functional Implications

  2014cited by this paper
• Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014influential reference
• ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Non–Small Cell Lung Cancer Expressing EML4-ALK

  2013cited by this paper
• Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis

  2012cited by this paper
• Diminished Functional Role and Altered Localization of Shp2 in Non-Small Cell Lung Cancer Cells With Egfr-Activating Mutations

  2012cited by this paper
• B7-H1 limits the entry of effector CD8+ T cells to the memory pool by upregulating Bim

  2012cited by this paper
• Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation

  2012cited by this paper
• Bim-mediated apoptosis and PD-1/PD-L1 pathway impair reactivity of PD1(+)/CD127(-) HCV-specific CD8(+) cells targeting the virus in chronic hepatitis C virus infection.

  2011cited by this paper
• IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity

  2011influential reference
• Modulation of T-cell activation by malignant melanoma initiating cells.

  2010cited by this paper
• Targeting protein tyrosine phosphatases for anticancer drug discovery.

  2010cited by this paper
• Tumor and Stem Cell Biology Cancer Research Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

  2010influential reference
• SHP‐1 and SHP‐2 in T cells: two phosphatases functioning at many levels

  2009cited by this paper
• Melanoma

  2006cited by this paper
• SHP‐1 suppresses cancer cell growth by promoting degradation of JAK kinases

  2003cited by this paper

• Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects

  2026cites this paper
• Tumor cell-intrinsic PD-1 regulates chemotherapy resistance in colorectal cancer cells by activating downstream MAPK signaling

  2025cites this paper
• Claudin-4 as a dual regulator of genome stability and immune evasion in high grade serous ovarian cancer

  2025cites this paper
• shRNA-based PD-1 suppression preserves memory phenotype and function of CD19-targeted CAR-T cell

  2025cites this paper
• PD-1, PD-L1, and PD-L2 Expression as Predictive Markers in Rare Feline Mammary Tumors

  2025cites this paper
• SHP2 is a multifunctional target in anaplastic thyroid carcinoma: Cell intrinsic and immune-dependent anti-tumor effects.

  2025cites this paper
• Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion.

  2025cites this paper
• PDCD1 expression increases at elevated temperatures

  2025cites this paper
• TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives

  2025cites this paper
• Programmed cell death protein 1 in cancer cells

  2025influential citation
• Engineered PD-L1 co-expression in PD-1 knockout and MAGE-C2-targeting TCR-T cells augments the cytotoxic efficacy toward target cancer cells

  2025cites this paper
• Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond.

  2025cites this paper
• Interaction of SMAC with a survivin-derived peptide alters essential cancer hallmarks: Tumor growth, inflammation, and immunosuppression

  2024cites this paper
• Exploring the clinical significance of IL-38 correlation with PD-1, CTLA-4, and FOXP3 in colorectal cancer draining lymph nodes

  2024cites this paper
• The immune checkpoint LAG-3 is expressed by melanoma cells and correlates with clinical progression of the melanoma

  2024cites this paper
• PD-1 interactome in osteosarcoma: identification of a novel PD-1/AXL interaction conserved between humans and dogs

  2024cites this paper
• Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies

  2024cites this paper
• PD-L2 of tumor-derived exosomes mediates the immune escape of cancer cells via the impaired T cell function

  2024cites this paper
• The Expression of PDL-1 and PD1 in the Microenvironment of Oral Squamous Cell Carcinoma

  2024cites this paper
• Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors

  2024cites this paper
• Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade

  2024cites this paper
• Expression of programmed cell death protein 1 and programmed cell death ligand 1 in feline injection site fibrosarcomas.

  2024cites this paper
• Expression of Immune Checkpoint Regulator Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) and Programmed Cell Death Protein Ligand 1 (PD-L1) in Invasive Ductal Carcinoma Breast

  2024cites this paper
• Regulatory mechanisms of PD-1/PD-L1 in cancers

  2024cites this paper
• Multifaceted roles of PD‐1 in tumorigenesis: From immune checkpoint to tumor cell‐intrinsic function

  2024cites this paper
• Alpha-fetoprotein upregulates hepatocellular carcinoma cell-intrinsic PD-1 expression through the LATS2/YAP/TEAD1 pathway.

  2024cites this paper
• Tumor cell–intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling

  2024cites this paper
• Immune Checkpoint Receptor/Ligand Expression and Chemotherapy in Colorectal Cancer

  2023cites this paper
• Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.

  2023cites this paper
• Diphtheria toxin‐derived, anti‐PD‐1 immunotoxin, a potent and practical tool to selectively deplete PD‐1+ cells

  2023cites this paper
• PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade

  2023cites this paper
• C. tropicalis promotes CRC by down-regulating tumor cell-intrinsic PD-1 receptor via autophagy

  2023cites this paper
• Coupled deglycosylation-ubiquitination cascade in regulating PD-1 degradation by MDM2.

  2023cites this paper
• Adenosine Methylation Level of miR-125a-5p Promotes Anti-PD-1 Therapy Escape through the Regulation of IGSF11/VSIG3 Expression

  2023cites this paper
• Increased death and exhaustion of CD69high T cells and NK cells are associated with PD-1 antibody application in the in vitro co-culture system

  2023cites this paper
• Neural induction drives body axis formation during embryogenesis, but a neural induction-like process drives tumorigenesis in postnatal animals

  2023cites this paper
• Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients

  2023cites this paper
• Variable Intrinsic Expression of Immunoregulatory Biomarkers in Breast Cancer Cell Lines, Mammospheres, and Co-Cultures

  2023cites this paper
• Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence

  2023cites this paper
• Sensing context: Inhibitory receptors on non‐hematopoietic cells

  2023cites this paper
• Paradoxical cancer cell stimulation by IFNγ drives tumor hyperprogression upon checkpoint blockade immunotherapy.

  2023cites this paper
• Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy

  2022cites this paper
• Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review)

  2022cites this paper
• Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events

  2022cites this paper
• In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies

  2022cites this paper
• Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion

  2022cites this paper
• Current Understanding and Future Perspectives on Hyperprogressive Disease Highlight the Tumor Microenvironment

  2022cites this paper
• Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?

  2022cites this paper
• Blockade of PD-L1/PD-1 signaling promotes osteo-/odontogenic differentiation through Ras activation

  2022cites this paper
• Alternatively mechanistic insights into acetylation in p53-mediated transcriptional regulation of cancer cell-intrinsic PD-1

  2022cites this paper
• Integrative multi-omics analysis reveals molecular subtypes and tumor evolution of synovial sarcoma

  2022cites this paper
• Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy

  2022cites this paper
• Modulation of Lymphocyte Functions in the Microenvironment by Tumor Oncogenic Pathways

  2022cites this paper
• Hematologic malignancies following immune checkpoint inhibition for solid tumors

  2022cites this paper
• Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies

  2022cites this paper
• Antibody-mediated depletion of programmed death 1-positive (PD-1+) cells

  2022cites this paper
• Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells

  2022cites this paper
• Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis

  2022influential citation
• Immunotherapies of retinoblastoma: Effective methods for preserving vision in the future

  2022cites this paper
• A comprehensive review of SHP2 and its role in cancer

  2022influential citation
• Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells

  2022cites this paper
• The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology

  2022cites this paper
• YB-1 promotes cell proliferation and metastasis by targeting cell-intrinsic PD-1/PD-L1 pathway in breast cancer.

  2022cites this paper
• Expression of programmed cell death-1 on neuroblastoma cells in TH-MYCN transgenic mice

  2022cites this paper
• Acetylcholine receptor binding antibody–associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review

  2022cites this paper
• Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)

  2022cites this paper
• IFN-γ and CD38 in Hyperprogressive Cancer Development

  2021cites this paper
• Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy

  2021cites this paper
• PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NFκB pathway

  2021cites this paper
• Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab

  2021cites this paper
• Repurposing Radiation Therapy for Immuno-oncology.

  2021cites this paper
• Expression of cancer cell-intrinsic PD-1 associates with PD-L1 and p-S6 and predicts a good prognosis in nasopharyngeal carcinoma

  2021cites this paper
• Hyperprogression under immunotherapy: a new form of immunotherapy response?—a narrative literature review

  2021cites this paper
• The Clinical and Biological Effects of PD-1 Expression on Tumor Cells in Diffuse Large B-Cell Lymphoma

  2021cites this paper
• New insights into the important roles of tumor cell-intrinsic PD-1

  2021cites this paper
• Evaluating the efficacy and safety of immune checkpoint inhibitors by detecting the exposure-response: An inductive review.

  2021cites this paper
• Hyperprogressive Disease: Main Features and Key Controversies

  2021cites this paper
• An unexpected role for p53 in regulating cancer cell–intrinsic PD-1 by acetylation

  2021cites this paper
• Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer

  2021cites this paper
• Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel

  2021cites this paper
• Hyperprogressive disease after radiotherapy combined with anti-PD-1 therapy in renal cell carcinoma: a case report and review of the literature

  2021influential citation
• Non-canonical PD-1 signaling in cancer and its potential implications in clinic

  2021cites this paper
• Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments.

  2021cites this paper
• Immune Therapy Resistance and Immune Escape of Tumors

  2021cites this paper
• Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)

  2021cites this paper
• RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature

  2020cites this paper
• Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy

  2020cites this paper
• Regulation of Cancer Immune Checkpoint: Mono- and Poly-Ubiquitination: Tags for Fate.

  2020cites this paper
• Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs

  2020cites this paper
• Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer

  2020cites this paper
• Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy

  2020cites this paper
• Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy

  2020cites this paper
• Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma

  2020cites this paper
• Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.

  2020cites this paper
• PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells

  2020cites this paper
• Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know

  2020cites this paper
• Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.

  2020cites this paper
• The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment

  2020cites this paper
• Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3 and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.

  2020cites this paper
• A cell-autonomous PD-1/PD-L1 circuit promotes tumorigenicity of thyroid cancer cells by activating a SHP2/Ras/MAPK signalling cascade

  2020cites this paper